MX421254B - Método para la conservación de material biológico. - Google Patents

Método para la conservación de material biológico.

Info

Publication number
MX421254B
MX421254B MX2020000480A MX2020000480A MX421254B MX 421254 B MX421254 B MX 421254B MX 2020000480 A MX2020000480 A MX 2020000480A MX 2020000480 A MX2020000480 A MX 2020000480A MX 421254 B MX421254 B MX 421254B
Authority
MX
Mexico
Prior art keywords
biopharmaceuticals
methods
conventional lyophilizer
lyophilizer
aseptic drying
Prior art date
Application number
MX2020000480A
Other languages
English (en)
Other versions
MX2020000480A (es
Inventor
Victor Bronshtein
Original Assignee
Universal Stabilization Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universal Stabilization Tech Inc filed Critical Universal Stabilization Tech Inc
Publication of MX2020000480A publication Critical patent/MX2020000480A/es
Publication of MX421254B publication Critical patent/MX421254B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26—DRYING
    • F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00—Drying solid materials or objects by processes not involving the application of heat
    • F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
    • F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26—DRYING
    • F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B9/00—Machines or apparatus for drying solid materials or objects at rest or with only local agitation; Domestic airing cupboards
    • F26B9/06—Machines or apparatus for drying solid materials or objects at rest or with only local agitation; Domestic airing cupboards in stationary drums or chambers
    • F26B9/066—Machines or apparatus for drying solid materials or objects at rest or with only local agitation; Domestic airing cupboards in stationary drums or chambers the products to be dried being disposed on one or more containers, which may have at least partly gas-previous walls, e.g. trays or shelves in a stack
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Mechanical Engineering (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La divulgación se refiere a métodos de ejecución de protocolos de PBV para preservar material biológico utilizando un liofilizador convencional. También se describen las etapas para mantener el aislamiento de un material biológico para lograr un secado aséptico utilizando el liofilizador convencional. Como beneficio colateral, la invención proporciona métodos compatibles con las buenas prácticas de fabricación (GMP) para lograr el secado aséptico de composiciones de material biológico utilizando un liofilizador convencional dispuesto fuera del área de un cuarto aséptico. Finalmente, se describen métodos y formulaciones para preservar material biológico adecuado para la administración a la mucosa o la administración transdérmica a un paciente.
MX2020000480A 2017-07-11 2018-07-11 Método para la conservación de material biológico. MX421254B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762604591P 2017-07-11 2017-07-11
PCT/US2018/041626 WO2019014338A1 (en) 2017-07-11 2018-07-11 METHOD FOR PRESERVING BIOPHARMACEUTICAL PRODUCTS

Publications (2)

Publication Number Publication Date
MX2020000480A MX2020000480A (es) 2020-09-10
MX421254B true MX421254B (es) 2025-02-10

Family

ID=65002200

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000480A MX421254B (es) 2017-07-11 2018-07-11 Método para la conservación de material biológico.

Country Status (9)

Country Link
US (1) US11400051B2 (es)
EP (1) EP3655000B1 (es)
JP (1) JP7198264B2 (es)
CN (1) CN111163789B (es)
AU (1) AU2018301395B2 (es)
BR (1) BR112020000592A2 (es)
CA (1) CA3069444A1 (es)
MX (1) MX421254B (es)
WO (1) WO2019014338A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113646047B (zh) * 2019-02-15 2025-07-08 印度血清研究所私人有限公司 减毒活流感疫苗组合物和用于制备其的方法
CN115151772B (zh) * 2020-02-04 2024-11-15 瑞泽恩制药公司 冻干药物产品的目标残留水分含量
US12085337B2 (en) * 2021-10-20 2024-09-10 DSM Sales & Manufacturing, Inc. Freeze-drying systems and methods
NO349529B1 (no) * 2024-07-23 2026-02-16 Oddvar Ingve Bjordal Frysetørking av porsjoner av biologisk materiale

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0092329B1 (en) * 1982-04-07 1988-07-27 Bernard Paul Philippe Feinmann Improved material and method for dentistry
US4780964A (en) * 1987-11-30 1988-11-01 Fts Systems, Inc. Process and device for determining the end of a primary stage of freeze drying
CN1286725A (zh) * 1997-11-26 2001-03-07 环球保藏技术股份有限公司 敏感性生物样品的玻化保质法
EP2319826A1 (en) * 2001-02-12 2011-05-11 Wyeth LLC Succinate salt of O-desmethyl-venlafaxin
US20030068416A1 (en) * 2001-09-24 2003-04-10 Wilson Burgess Method of lyophylization to reduce solvent content and enhance product recovery
WO2003087327A2 (en) * 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
US20100120014A1 (en) * 2002-06-18 2010-05-13 Victor Bronshtein Stability Drying
FR2852329A1 (fr) * 2003-03-14 2004-09-17 Univ Aix Marseille Ii Cellules lyophilisees et procede de lyophilisation permettant l'obtention desdites cellules
CN1241474C (zh) * 2003-09-03 2006-02-15 江西省科学院住友生物工程技术有限公司 生物羊膜保存处理方法
JP2005201746A (ja) * 2004-01-15 2005-07-28 Ebara Corp 有機溶媒抽出に供する疎水性化合物を含む被験試料の前処理方法
AU2012204056B2 (en) * 2004-06-02 2013-11-07 Victor Bronshtein Preservation by vaporization
EP2567708A3 (en) * 2004-06-02 2013-10-16 Victor Bronshtein Preservation by vaporization
EP1909736B1 (en) * 2005-08-02 2014-11-12 Baxter International Inc. Oxygen indicator for use in medical products and packet containing oxygen indicator
CN1757414A (zh) * 2005-09-09 2006-04-12 中国海洋大学 一种治疗眼表疾病的载药可视多糖膜片的制造方法
US8793895B2 (en) * 2006-02-10 2014-08-05 Praxair Technology, Inc. Lyophilization system and method
EP1870649A1 (en) * 2006-06-20 2007-12-26 Octapharma AG Lyophilisation targetting defined residual moisture by limited desorption energy levels
WO2008011683A1 (en) * 2006-07-28 2008-01-31 Resmed Ltd Delivery of respiratory therapy
EP2148923B1 (en) * 2007-05-18 2012-08-22 MedImmune, LLC Preservation of bioactive materials by freeze dried foam
CN103858859B (zh) * 2008-06-27 2015-11-04 博傲沃德株式会社 细胞及组织的冷冻保存用组合物
AU2010254235B2 (en) * 2009-05-26 2015-04-02 Advanced Bionutrition Corporation Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
MX350047B (es) * 2010-08-13 2017-08-24 Advanced Bionutrition Corp Composicion de estabilizacion de almacenamiento en seco para materiales biologicos.
BR112014020930A2 (pt) * 2012-03-05 2017-06-27 De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport método para produzir uma formulação seca de um agente biofármaco, e, formulação de um agente biofármaco
WO2013135826A1 (en) * 2012-03-14 2013-09-19 Project Pharmaceutics Gmbh Improved lyophilization method
SG11201607642RA (en) * 2014-03-24 2016-10-28 Biogen Ma Inc Lyophilized factor ix formulations
CN104488853B (zh) * 2015-01-12 2016-08-24 中国农业大学 一种牛胚胎玻璃化冷冻甩管解冻和直接移植方法

Also Published As

Publication number Publication date
WO2019014338A1 (en) 2019-01-17
AU2018301395B2 (en) 2024-11-14
RU2020103377A3 (es) 2022-03-31
JP7198264B2 (ja) 2022-12-28
BR112020000592A2 (pt) 2020-07-14
MX2020000480A (es) 2020-09-10
AU2018301395A2 (en) 2020-02-20
CN111163789A (zh) 2020-05-15
EP3655000B1 (en) 2026-01-14
JP2020526225A (ja) 2020-08-31
EP3655000A1 (en) 2020-05-27
EP3655000A4 (en) 2021-07-14
US11400051B2 (en) 2022-08-02
EP3655000C0 (en) 2026-01-14
RU2020103377A (ru) 2021-08-11
CA3069444A1 (en) 2019-01-17
CN111163789B (zh) 2024-04-09
US20210145751A1 (en) 2021-05-20
AU2018301395A1 (en) 2020-02-06

Similar Documents

Publication Publication Date Title
CY1122038T1 (el) Ετεροδιλειτουργικοι αναστολεις των ε-σελεκτινων και των υποδοχεων χημειοκινης cxcr4
CO2021006308A2 (es) Proteínas f de prefusión del vrs estabilizadas
CL2019001128A1 (es) Proteínas insecticidas.
CL2017003226A1 (es) Reguladores nrf2
CL2018002826A1 (es) Proteínas f de prefusión del virus respiratorio sincicial (vrs) solubles y estabilizadas
MX2020000480A (es) Método para la conservación de material biológico.
DK3542635T3 (da) Valleproteinbaseret yoghurtlignende produkt med højt proteinindhold, ingrediens egnet til fremstilling deraf og fremgangsmåde til fremstilling.
PT3337829T (pt) Método e composição para o tratamento do cancro, matando células cancerosas metastáticas e prevenindo as metástases do cancro usando anticorpos para produtos finais de glicação avançada (pga)
MX2018015749A (es) Formulacion de una vacuna peptidica.
BR112017004393A2 (pt) formulações de anticorpo
HK1258016A1 (zh) 可吸入烟硷制剂以及其制备和使用方法
MX374129B (es) Proceso para la preparación de eritrocitos cargados con una o más sustancias de interés farmacéutico y eritrocitos así obtenidos.
BR112017009651A2 (pt) composto, composição farmacêutica, e, método para tratamento de uma infecção por protozoário intracelular, uma infecção viral ou um câncer.
CL2015001772A1 (es) Composición farmacéutica para el tratamiento de dolor cabeza, y método de preparación de la misma.
DK3582622T3 (da) Syrnet flydende mejeriprodukt med højt proteinindhold og med en reduceret viskositet, fremgangsmåde til fremstilling deraf og relaterede bestanddele
HK1259441A1 (zh) 包含btk抑制剂的制剂/组合物
DK3604304T3 (da) Pyrrolo-pyridinderivatforbindelse, fremgangsmåde til fremstilling deraf og farmaceutisk sammensætning indeholdende denne som aktiv ingrediens til forebyggelse eller behandling af proteinkinase-relaterede sygdomme
DK3744316T3 (da) Oftalmisk farmaceutisk sammensætning, fremgangsmåde til fremstilling deraf og anvendelse deraf
EP3538124A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES, HYPERTENSION AND HYPERCHOLESTEROLEMIA
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
MX385925B (es) Oritavancina de alta pureza y método para producir la misma.
BR112018008769A2 (pt) formulações farmacêuticas, formulações líquidas aquosa reconstituída e liofilizada, seringa, método de fabricação de uma formulação farmacêutica, método para tratamento de uma doença e uso de uma formulação reconstruída
BR112017012799A2 (pt) combinações de composto ativo que compreendem um derivado de (tio)carboxamida e composto(s) fungicida(s).
EP3564338A4 (en) LIGHT ACCUMULATING FLUORESCENT BODY AS WELL AS A METHOD FOR MAKING THE SAME, AND LIGHT ACCUMULATING ARTICLE
IL285337A (en) Compositions for cryopreservation of a biological material